Athina Stravodimou

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


52 publications

En préparation
 
Distinct immune signatures are a potent tool in the clinical management of cytokine-related syndrome during immune checkpoint therapy
Daoudlarian Douglas, Segot Amandine, Latifyan Sofiya, Bartolini Robin, Joo Victor, Mederos Nuria, Bouchaab Hasna, Demicheli Rita, Abdelhamid Karim, Ferahta Nabila et al..
[DOI][serval:BIB_818D0F24F67B]
 
Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study
Petit Pierre-Florent, Daoudlarian Douglas, Latifyan Sofiya, Bouchaab Hasna, Mederos Nuria, Doms Jacqueline, Abdelhamid Karim, Ferahta Nabila, Mencarelli Lucrezia, Joo Victor et al..
[DOI][serval:BIB_34BED0C92D50]
Sous presse
 
Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapy
Daoudlarian D., Segot A., Latifyan S., Bartolini R., Joo V., Mederos N., Bouchaab H., Demicheli R., Abdelhamid K., Ferahta N. et al. Annals of Oncology. Peer-reviewed.
[DOI][Pmid][serval:BIB_6B38C9E34CAB]
2025
 
Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study.
Petit P.F., Daoudlarian D., Latifyan S., Bouchaab H., Mederos N., Doms J., Abdelhamid K., Ferahta N., Mencarelli L., Joo V. et al., 2025/01. Annals of oncology, 36 (1) pp. 43-53. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_0BA6393BFB37]
2024
 
Deep mapping of the cytokine release syndrome inflammatory continuum: Comprehensive grade-specific profiling and differentiation from sepsis in patients receiving immune checkpoint therapy.
Obeid Michel, Daoudlarian Douglas, Segot Amandine, Latifyan Sofiya, Bouchaab Hasna, Mederos Nuria, Abdelhamid Karim, Ferahta Nabila, Stravodimou Athina, Shabafrouz Keyvan et al., 2024/06/01. pp. 12129-12129 dans Journal of Clinical Oncology, American Society of Clinical Oncology (ASCO).
[DOI][serval:BIB_928272EB14D0]
 
Cancer du sein chez l’homme : un combat méconnu [Male breast cancer: a lesser-known battle]
Benchaa H., Stravodimou A., 2024/05/15. Revue medicale suisse, 20 (874) pp. 968-972. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_DD757126534F]
A pharmacist-led interprofessional medication adherence program improved adherence to oral anticancer therapies: The OpTAT randomized controlled trial.
Bandiera C., Cardoso E., Locatelli I., Zaman K., Diciolla A., Digklia A., Stravodimou A., Cristina V., Aedo-Lopez V., Dolcan A. et al., 2024. PloS one, 19 (6) pp. e0304573. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_43D02C36CEB4]
 
Neo-adjuvant therapies for ER positive/HER2 negative breast cancers: from chemotherapy to hormonal therapy, CDK inhibitors, and beyond.
Stravodimou A., Voutsadakis I.A., 2024. Expert review of anticancer therapy, 24 (3-4) pp. 117-135. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_8D56E74D4A72]
2023
Cytokine storm complicated by cardiogenic shock induced by anti-HER2 therapies.
Godinho R., Noto A., Fenwick C., Stravodimou A., Hugelshofer S., Peters S., Hullin R., Obeid M., 2023/06. Journal for immunotherapy of cancer, 11 (6). Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D3B4F544BDF7]
 
Feasibility of treatment with another CDK4/6 inhibitor after severe ribociclib liver toxicity.
Zurcher Jean-Philippe, Goujon Morgan, Cottu Paul H., Desmoulins Isabelle, Teixeira Luis, Mansi Laura, Meynard Guillaume, Dobi Erion, Rowinski Elise, Stacoffe Marion et al., 2023/06/01. pp. e13067-e13067 dans Journal of Clinical Oncology. Peer-reviewed.
[DOI][serval:BIB_B01DDDA0C38A]
Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides BRCA1 and BRCA2 as Breast Cancer Biomarkers for PARP Inhibitors and Other DDR Targeting Therapies.
Voutsadakis I.A., Stravodimou A., 2023/03. Anticancer research, 43 (3) pp. 967-981. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_3961434FC488]
 
Oncologie : ce qui a changé en 2022 [Oncology: what's new in 2022]
Nguyen-Ngoc T., Abdelhamid K., Degrauwe N., Galland S., Serena A., Christofis M., Mederos N., Bouchaab H., Diciolla A., Dris N. et al., 2023/01/18. Revue medicale suisse, 19 (N° 809-10) pp. 52-57. Peer-reviewed.
[DOI][Pmid][serval:BIB_FAF585D3813B]
Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study.
Bandiera C., Locatelli I., Courlet P., Cardoso E., Zaman K., Stravodimou A., Dolcan A., Sarivalasis A., Zurcher J.P., Aedo-Lopez V. et al., 2023/01/03. Cancers, 15 (1) p. 316. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2263B25B85EB]
 
An interprofessional medication adherence program to optimize adherence to oral anticancer therapies: a randomized-controlled trial
Bandiera C., Cardoso E., Locatelli I., Digklia A., Zaman K., Diciolla A., Cristina V., Stravodimou A., Lopez V.A., Dolcan A. et al., 2023., 26th International Society for Medication Adherence (ESPACOMP) Conference p. 269 dans International Journal of Clinical Pharmacy. Peer-reviewed.
[DOI][Pmid][serval:BIB_944A7B3041CF]
2022
Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer.
Courlet P., Cardoso E., Bandiera C., Stravodimou A., Zurcher J.P., Chtioui H., Locatelli I., Decosterd L.A., Darnaud L., Blanchet B. et al., 2022/06/21. Pharmaceutics, 14 (7) p. 1317. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_E7FBC59504B2]
Estrogen receptor positive breast cancers have patient specific hormone sensitivities and rely on progesterone receptor.
Scabia V., Ayyanan A., De Martino F., Agnoletto A., Battista L., Laszlo C., Treboux A., Zaman K., Stravodimou A., Jallut D. et al., 2022/06/06. Nature communications, 13 (1) p. 3127. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_BED35CC8098E]
Effets indésirables des nouvelles thérapies du cancer du sein : quand faut-il réagir ? [Adverse effects of new breast cancer therapies : when to react ?]
Dris N., Meyer M.L., Flores Torres C., Curtit E., Zurcher J.P., Stravodimou A., Zaman K., 2022/05/18. Revue medicale suisse, 18 (782) pp. 997-1001. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_6573A443A776]
Neurotrophic receptor tyrosine kinase family members in secretory and non-secretory breast carcinomas.
Stravodimou A., Voutsadakis I.A., 2022/02/24. World journal of clinical oncology, 13 (2) pp. 135-146. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_145ED5AE75A7]
Oncologie [2021 Oncology update]
Meyer M.L., Chrysou K., Stamatiou A., Gilabert M., Herrera Gomez R.G., Latifyan S., Masmoudi S., Mederos N., Perrinjaquet C., Berthold D. et al., 2022/02/02. Revue medicale suisse, 18 (767) pp. 182-186. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_BB8819FD3196]
2021
 
Chemotherapy and targeted treatments of breast sarcoma by histologic subtype.
Kokkali S., Stravodimou A., Duran-Moreno J., Koufopoulos N., Voutsadakis I.A., Digklia A., 2021/06. Expert review of anticancer therapy, 21 (6) pp. 591-604. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_A06BD9846D13]
Cancer du sein chez la femme en [Breast cancer during pregnancy]
Schnetz M., Stravodimou A., Cisarovsky C., Dunand A., Prior J.O., Nicod Lalonde M., Baud D., Meuwly J.Y., Winterfeld U., Zaman K., 2021/05/19. Revue medicale suisse, 17 (739) pp. 957-961. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_80DEB9D1E4CC]
Intraductal xenografts show lobular carcinoma cells rely on their own extracellular matrix and LOXL1.
Sflomos G., Battista L., Aouad P., De Martino F., Scabia V., Stravodimou A., Ayyanan A., Ifticene-Treboux A., RLS, Bucher P. et al., 2021/03/05. EMBO molecular medicine, 13 (3) pp. e13180. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7FB2372AC0AF]
Oncologie [2020 oncology update]
Dei Tos G., Galli Vareia I., Huber A., Wolf B., Diciolla A., Herrera Gomez R.G., Wagner D., Digklia A., Bouchaab H., Cristina V. et al., 2021/01/27. Revue medicale suisse, 17 (723) pp. 201-205. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_25D6152EB267]
Optimizing oral targeted anticancer therapies study for patients with solid cancer: Protocol for a randomized controlled medication adherence program along with systematic collection and modeling of pharmacokinetic and pharmacodynamic data.
Bandiera C., Cardoso E., Locatelli I., Digklia A., Zaman K., Diciolla A., Cristina V., Stravodimou A., Lopez V.A., Dolcan A. et al., 2021. JMIR Research Protocols, 10 (6) pp. e30090. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_7657CD7990C9]
2020
 
The Future of ER+/HER2- Metastatic Breast Cancer Therapy: Beyond PI3K Inhibitors.
Stravodimou A., Voutsadakis I.A., 2020/09. Anticancer research, 40 (9) pp. 4829-4841. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1228E171873C]
Oncology during the COVID-19 pandemic: challenges, dilemmas and the psychosocial impact on cancer patients.
Tsamakis K., Gavriatopoulou M., Schizas D., Stravodimou A., Mougkou A., Tsiptsios D., Sioulas V., Spartalis E., Sioulas A.D., Tsamakis C. et al., 2020/07. Oncology letters, 20 (1) pp. 441-447. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_B80FE975C205]
Cancer du sein: perspectives de médecine intégrative [Breast cancer: perspectives from integrative medicine]
Stravodimou A., Zurron N., Fleury M., Stanic J., Ramos Chapuis M., Eicher M., Berna C., Zaman K., 2020/05/27. Revue medicale suisse, 16 (695) pp. 1102-1105. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_0DCBDD7111BC]
 
Abstract P6-10-22: miR363-3p mediates maintenance of breast cancer stem cells (BCSCs) and predicts resistance to neoadjuvant chemotherapy and disease recurrence
Renaud Stephanie, Stravodimou Athina, Fiche Maryse, Xenarios Ioannis, Valentina Scabia, Dormoy Valerian, Galmiche Marie, Brisken Cathrin, Delaloye Jean-Francois, Treboux Assia et al., 2020/02/15. pp. P6-10-22-P6-10-22 dans Cancer Research.
[DOI][WoS][serval:BIB_3268070F9DED]
 
Tout à coup elle a entendu des voix
Robert Julie, Blondet Fanny, Stravodimou Athina, Bouclin Thierry, Monti Matteo, 2020/02/11. Forum Médical Suisse ‒ Swiss Medical Forum.
[DOI][serval:BIB_DAB55DA6AB1E]
Oncologie [Advances in Oncology 2019]
Vernadou A., Ferahta N., Mederos N., Ferraro D., Dischl-Antonioni I., Diciolla A., Liapi A., Mosimann V., Latifyan S., Aedo-Lopez V. et al., 2020/01/15. Revue medicale suisse, 16 (676-7) pp. 72-77. Peer-reviewed.
[URN][Pmid][serval:BIB_7B31C4DA5F5B]
2019
 
A Systematic Review and Meta-analysis of the Combination of Vinorelbine and Lapatinib in Patients With Her2-positive Metastatic Breast Cancer.
Stravodimou A., Voutsadakis I.A., 2019/07. Anticancer research, 39 (7) pp. 3295-3301. Peer-reviewed.
[DOI][Pmid][serval:BIB_798BD609E807]
Nouvelles stratégies thérapeutiques dans les cancers mammaire et tubo-ovarien de stade avancé [New therapeutic strategies in advanced stage breast and tubo-ovarian cancers]
Nikolopoulou A., Galli-Vareia I., Stravodimou A., Sarivalasis A., Zaman K., 2019/05/15. Revue medicale suisse, 15 (651) pp. 1027-1031. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_44ECB7C03967]
Intraductal patient-derived xenografts of estrogen receptor α-positive breast cancer recapitulate the histopathological spectrum and metastatic potential of human lesions.
Fiche M., Scabia V., Aouad P., Battista L., Treboux A., Stravodimou A., Zaman K., RLS, Dormoy V., Ayyanan A. et al., 2019/03. The Journal of pathology, 247 (3) pp. 287-292. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_86A544986D24]
 
Oncologie [Oncology, what's new in 2018]
Latifyan S., Kakourou A., Ozdemir B., Zaman K., Vernadou A., Berthold D., Abdelhamid K., Bouchaab H., Peters S., Montemurro M. et al., 2019/01/09. Revue medicale suisse, 15 (N° 632-633) pp. 78-81. Peer-reviewed.
[Pmid][serval:BIB_E686DFA1B1CC]
2018
 
Efficacy and safety of the CDK4/6 inhibitor palbociclib during different lines of treatment in patients with advanced stage endocrine sensitive/HER2 negative breast cancer.
Zurcher Jean-Philippe, Aedo Veronica, Stravodimou Athina, Sarivalasis Apostolos, Zaman Khalil, 2018/05/20. Journal of Clinical Oncology, 36 (15_suppl) pp. e13052-e13052.
[DOI][WoS][serval:BIB_899C43F0DBF7]
 
Adjuvant pertuzumab (PER) for HER2-positive early stage breast cancer (eBC): A Swiss experience
Stravodimou A., Bodmer A., Aedo Lopez V., Zurcher J.P., Zaman K., 2018/04. European Journal of Cancer, 92 pp. S93.
[DOI][serval:BIB_7F2F9C828B3A]
2017
 
Abstract P2-05-11: miR363-3p mediates maintenance and resistance of breast cancer stem cells (BCSC)
Renaud S, Fiche M, Stravodimou A, Scabia V, Dormoy VM, Galmiche Rindisbacher M, Brisken C, Mermod N, Zaman K, 2017/02/15. pp. P2-05-11-P2-05-11 dans Cancer Research.
[DOI][WoS][serval:BIB_0997659E079F]
2016
 
Hormonothérapie dans le cancer du sein invasif, update 2016 [Hormone therapy in invasive breast cancer : update 2016]
Zurcher J.P., Stravodimou A., Zaman K., 2016/09/21. Revue medicale suisse, 12 (531) pp. 1580-1583. Peer-reviewed.
[Pmid][serval:BIB_50C445402734]
 
Mutations de BRCA1/2: d'Angelina Jolie à la thérapie [BRCA mutations: from Angelina Jolie to specific therapies]
Lopez V.A., Stravodimou A., Unger S., Perey L., Zaman K., 2016/05/18. Revue medicale suisse, 12 (519) pp. 973-974,976-977. Peer-reviewed.
[Pmid][serval:BIB_0D4DB284C1A0]
2015
 
Clinical utility of a molecular test in adjuvant treatment decision making in women with endocrine-sensitive early stage breast cancer: a retrospective, single center one year experience
Stravodimou A., Silverio C., Nicoulaz AL, Wolfer A., Perey L., Delaloye JF, Zaman K., Fiche M., 2015. p. 636 dans 81. Jahrestagung der Schweizerischen Gesellschaft für Pathologie, Der Pathologe.
[DOI][serval:BIB_B309378449FC]
 
Perivascular epithelioid cell tumor (PEComa) of the uterus: A case report
Caseiro Silverio P., Achtari C., Stravodimou A., Fiche M., 2015. p. 625 dans 81. Jahrestagung der Schweizerischen Gesellschaft für Pathologie, Der Pathologe.
[DOI][serval:BIB_B85B8DD7F2A0]
2014
 
Personalized Treatment of Advanced Non-small Cell Lung Cancer: EGFR Tyrosine Kinase Inhibitors as a Standard of Care
Stravodimou Athina, Peters Solange, 2014/12/05. The Journal of OncoPathology, 1 (4) pp. 63-71.
[DOI][serval:BIB_34A93A287504]
 
Résistance à l'endocrinothérapie dans le cancer du sein: mécanismes et implications cliniques [Endocrine therapy resistance in metastatic breast cancer: mechanisms and clinical implications]
Orcurto A., Odermatt R., Stravodimou A., Wolfer A., 2014/05/21. Revue medicale suisse, 10 (431) pp. 1102-1106. Peer-reviewed.
[Pmid][serval:BIB_40661CAC61F5]
MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein) in patients receiving autologous PBMCs after lymphodepletion: results of a Phase I trial.
Romano E., Michielin O., Voelter V., Laurent J., Bichat H., Stravodimou A., Romero P., Speiser D.E., Triebel F., Leyvraz S. et al., 2014. Journal of Translational Medicine, 12 p. 97.
[URN][DOI][WoS][Pmid][serval:BIB_09C5EADDDF4D]
Statin use and peripheral blood progenitor cells mobilization in patients with multiple myeloma.
Stravodimou A., Voutsadakis I.A., 2014. Clinical and Translational Oncology, 16 (1) pp. 85-90. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_061E0A8E0299]
Vinorelbine with or without Trastuzumab in Metastatic Breast Cancer: A Retrospective Single Institution Series
Stravodimou A., Zaman K., Voutsadakis I.A., 2014. Isrn Oncology, 2014 p. 289836. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_079DAD2E48CF]
2013
 
Effect of Melan-Α/Μart-1-peptide vaccination plus IMP321 on antitumor immunity and clinical benefit in patients receiving autologous PBMCs after lymphodepletion.
Romano Emanuela, Bichat Helene, Stravodimou Athina, Romero Pedro, Daniel Speiser E, Triebel Frederic, Michielin Olivier, Harari Alexander, Leyvraz Serge, 2013/05/20. Journal of Clinical Oncology, 31 (15_suppl) pp. e20011-e20011.
[DOI][serval:BIB_CEE152105C66]
Pretreatment Thrombocytosis as a Prognostic Factor in Metastatic Breast Cancer
Stravodimou A., Voutsadakis I.A., 2013. International Journal of Breast Cancer, 2013 p. 289563. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_BCFB133ABD49]
2012
 
Abstract P6-04-05: Tamoxifen dose escalation based on endoxifen level: a prospective trial with genotyping, phenotyping and pharmacokinetics over 4 months.
Zaman K, Dahmane E, Perey L, Bodmer A, Anchisi S, Wolfer A, Galmiche M, Stravodimou A, Buclin T, Eap C et al., 2012/12/15. dans Poster Session Abstracts.
[DOI][serval:BIB_2F4DA182F478]
 
Hand and Foot Syndrome associated with docetaxel treatment.
Stravodimou A., Voutsadakis I.A., 2012. Acta Oncologica (stockholm, Sweden), 51 (4) pp. 554-556.
[DOI][WoS][Pmid][serval:BIB_705DF7F64F38]
Peroxisome proliferator-activated receptor gamma and regulations by the ubiquitin-proteasome system in pancreatic cancer.
Stravodimou A., Mazzoccoli G., Voutsadakis I.A., 2012. Ppar Research, 2012 p. 367450. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_179B9AF9D8C3]
PTLD Burkitt Lymphoma in a Patient with Remote Lymphomatoid Granulomatosis.
Stravodimou A., Cairoli A., Rausch T., Du Pasquier R., Michel P., 2012. Case Reports In Medicine, 2012 p. 239719.
[URN][DOI][Pmid][serval:BIB_AB92C502EDD1]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University